| Autor: |
Schmerling RA; Medical Oncologist at Centro Oncológico Antonio Ermírio de Moraes, São Paulo, Brazil. schmerling@gmail.com. |
| Jazyk: |
angličtina |
| Zdroj: |
Chinese clinical oncology [Chin Clin Oncol] 2014 Sep; Vol. 3 (3), pp. 31. |
| DOI: |
10.3978/j.issn.2304-3865.2014.08.03 |
| Abstrakt: |
Immunologic checkpoint inhibitor is a new class of antineoplastic drugs which mechanism of action depends on the interaction with the immune system. The first in class was ipilimumab, anti-CTLA4, and soon the anti-PD1 (Programmed Death 1) and anti-PDL1 are expected to be available. Although the profile of adverse events is unique, they are predictable and, by complying with the guidelines available, the management of these drugs is safe in the great majority of patients. Here, it is provided a review of adverse events and their management. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
